The immunoglobulin combination was separated and extracted from normal human plasma by the low-temperature ethanol method, and refined through further processing and virus inactivation steps. This product is a complete, unmodified natural lgG antibody with a purity of up to 98%. It contains no preservatives and antibiotics and is intended for intravenous infusion. Compared with intramuscular gamma globulin, it has a faster effect and a significant effect. advantage.
Market Analysis and Insights: Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market
Due to the COVID-19 pandemic, the global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 1g/20ml accounting for % of the Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) market size is valued at US$ million in 2021, while the US and Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) include Boya-Bio, Beijing Tiantan Biological Products, Hualan Bio, Guangdong Shuagnlin Bio-pharmacy, Weiguang Biological, Sinopharm, Shanghai RAAS, CTBB and Nanyue Biopharming. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Scope and Segment
Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
1g/20ml
1.25g/25ml
2.5g/50ml
5g/100ml
10g/200ml
Segment by Application
Hospital
Clinic
Others
By Company
Boya-Bio
Beijing Tiantan Biological Products
Hualan Bio
Guangdong Shuagnlin Bio-pharmacy
Weiguang Biological
Sinopharm
Shanghai RAAS
CTBB
Nanyue Biopharming
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE